These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9520369)

  • 21. Metabolite diversity in the plant pathogen Alternaria brassicicola: factors affecting production of brassicicolin A, depudecin, phomapyrone A and other metabolites.
    Pedras MS; Park MR
    Mycologia; 2015; 107(6):1138-50. PubMed ID: 26297782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export.
    Yoshida M; Horinouchi S
    Ann N Y Acad Sci; 1999; 886():23-36. PubMed ID: 10667200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereoselective Total Synthesis of (-)-Depudecin.
    García-Ruiz C; Cheng-Sánchez I; Sarabia F
    Org Lett; 2015 Nov; 17(22):5558-61. PubMed ID: 26517569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype.
    Kim MS; Son MW; Kim WB; In Park Y; Moon A
    Cancer Lett; 2000 Aug; 157(1):23-30. PubMed ID: 10893438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplasmodial compounds from the wood-decayed fungus Xylaria sp. BCC 1067.
    Isaka M; Jaturapat A; Kladwang W; Punya J; Lertwerawat Y; Tanticharoen M; Thebtaranonth Y
    Planta Med; 2000 Jun; 66(5):473-5. PubMed ID: 10909272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes.
    Gloushankova N; Ossovskaya V; Vasiliev J; Chumakov P; Kopnin B
    Oncogene; 1997 Dec; 15(24):2985-9. PubMed ID: 9416842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SCH 51344 inhibits ras transformation by a novel mechanism.
    Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
    Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of histone deacetylase as new anticancer agents.
    Jung M
    Curr Med Chem; 2001 Oct; 8(12):1505-11. PubMed ID: 11562279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression.
    Hassig CA; Tong JK; Fleischer TC; Owa T; Grable PG; Ayer DE; Schreiber SL
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3519-24. PubMed ID: 9520398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Morphological reversion of tumor cells by histone deacetylase inhibitors and radicicol].
    Yoshida M; Honda A; Horinouchi S
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1512-8. PubMed ID: 9309149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A role for Ras in v-Crk transformation.
    Greulich H; Hanafusa H
    Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
    Namdar M; Perez G; Ngo L; Marks PA
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, characterization, and evaluation of Cd[L-proline]
    Chidambaram A; Sekar A; S H K; Chidambaram RK; Arunachalam K; G P S; Vilwanathan R
    Invest New Drugs; 2017 Dec; 35(6):691-705. PubMed ID: 28776290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tropomyosin-2 cDNA lacking the 3' untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts.
    Janssen RA; Mier JW
    Mol Biol Cell; 1997 May; 8(5):897-908. PubMed ID: 9168473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated nuclear sphingoid base-1-phosphates and decreased histone deacetylase activity after fumonisin B1 treatment in mouse embryonic fibroblasts.
    Gardner NM; Riley RT; Showker JL; Voss KA; Sachs AJ; Maddox JR; Gelineau-van Waes JB
    Toxicol Appl Pharmacol; 2016 May; 298():56-65. PubMed ID: 26905748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
    Marampon F; Leoni F; Mancini A; Pietrantoni I; Codenotti S; Ferella L; Megiorni F; Porro G; Galbiati E; Pozzi P; Mascagni P; Budillon A; Maggio R; Tombolini V; Fanzani A; Gravina GL; Festuccia C
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):393-409. PubMed ID: 30474756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts.
    Seliger B; Pfizenmaier K; Schäfer R
    J Virol; 1991 Nov; 65(11):6307-11. PubMed ID: 1717721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
    Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
    Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation.
    Mai A; Massa S; Ragno R; Esposito M; Sbardella G; Nocca G; Scatena R; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2002 Apr; 45(9):1778-84. PubMed ID: 11960489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.